{
    "nctId": "NCT01661153",
    "briefTitle": "An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer",
    "officialTitle": "A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Locally recurrent or metastatic breast cancer\n* No prior treatment for metastatic or locally recurrent disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\nExclusion Criteria:\n\n* History or clinical evidence of brain metastases\n* Pregnancy\n* Uncontrolled hypertension ( systolic \\> 150 mmHg and/or diastolic \\> 100 mmHg) or clinically significant (i.e. active) cardiovascular disease\n* Major surgical procedure or significant traumatic injury within 28 days prior to enrolment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}